Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Katherine A. Thornton, Richard Pazdur, V. Ellen Maher et al.|Clinical Cancer Research|2012

Cited by 149